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Abstract: Co(II); Zn(II) and Cu(II) complexes oftwo new sulfonamide carbonic anhydrase (CA) inhibitors,
derivatives of thienothiopyran-2-sulfonamide, were prepared and characterized by analytic, spectroscopic,
magnetic and conductimetric measurements. The new complexes are more potent CA inhibitors than the
parent sulfonamides, with ICso values around 0.1 nM, against isozyme CA II.
Introduction
Heterocyclic sulfonamides were only recently investigated as complexing agents,1’2 although
some of them such as acetazolamide 1, methazolamide 2 ,or ethoxzolamide 3 are widely used clinical
agents
3 for the management of disorders associated with electrolyte secretion disequilibria.
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It was only recently reported
4 that the metal complexes of sulfonamides 1-3 behave as very
strong inhibitors of the zinc enzyme carbonic anhydrase (CA, EC 4.2.1.1). Their mechanism of action has
also been explained by this group.
4,5 Thus, this type of CA inhibitors possesses a dual mechanism of
inhibition, by means of sulfonamide anions and metal ions, formed by dissociation of the complexes in
dilute solutions during the enzymatic assay.
4 The sulfonamide anions bind thereafter to the catalytically
vital Zn(II) ion within the CA active site, whereas cations probably bind in the neighborhood of active site
residue His-64 (which acts as a proton shuttle during the catalytic turnover 6), disturbing in this way the
whole catalytic cycle.4’5 This dual mechanism also explains why metal complexes of heterocyclic
sulfonamides are much stronger CA inhibitors as compared to the parent ligand sulfonamide. 1’4’5
*Presented at EUROBIC II, Florence, Italy, August 1994.
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Recently, Merck
7 developed a novel class of water soluble CA inhibitorsk
derivatives of
thienothiopyran-2-sulfonamide, of type 4, which are topically active antiglaucoma agents.
,9 In this paper
we report the first complexation study with this class of pharmacologically important compounds, and on
the other hand, this is the first example in which a sulfonamide which does not possess endocyclic nitrogen
atoms as putative donor atoms, is used for preparing complexes. Practically, the two sulfonamides used for
the preparation of complexes are sezolamide 4a, HSZA ((R)-5,6-dihydro-4-(2-methylpropyl)amino-4H-
thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide) and dorzolamide 4b, HDZA (5,6-dihydro-(S)-4-
ethylamino-(S)-6-methyl-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide (both as hydrochlorides).
Both ligands were used as pure enantiomers: (R) in the case of 4a, and (S,S) in the case of 4b, which
contains two chiral centers. These are the enatiomers possessing the most potent CA inhibitory properties in
this class of compounds.
7,9 The actual drug is 4b, dorzolamide, recently introduced in clinical medicine in
USA, whereas 4a was the first compound from this class developed by Merck and abandoned thereafter for
4b, whicsh_toCOntaining a supplementary chiral center, presumably interacts more specifically with the
enzyme.
Materials and Methods
Melting points were recorded on a heating plate microscope and are not corrected. FTIR spectra
were obtained on thin films of pure compound, with a Perkin Elmer 1600 instrument, in the range 400
4000 cm-1. Electronic spectra were obtained by the diffuse reflectance technique in MgO as reference, with
a Perkin Elmer Lambda 17 apparatus. Conductimetric measurements were done in DMF solutions, at 25C
(concentrations of 1 mM of complex) with a Fisher conductimeter. Magnetic susceptibility measurements
were done at room temperature by Faraday’s method, using CoHg(NCS)4 as standard. Elemental analyses
were done by combustion for C,H,N with an automated Carlo Erba analyzer, and gravimetrically for the
metal ions, and were + 0.4% ofthe theoretical values.
Sulfonamides 4a,b used in the syntheses were prepared as described in the literature.
7 Metal
salts, organic reagents used for preparing the ligands 4 and solvents were from Aldrich and were used
without additional purification. Bovine CA II was from Sigma Chemical Co. Inhibitors were assayed by
Maren’s micromethod 10, in the conditions of the E-I (enzyme-inhibitor) technique, at 0C in veronal buffer.
ICs0 values represent the molarity of inhibitor producing a 50% decrease ofCA specific activity for the CO:
hydration reaction.
Synthesis of coordination compounds 5-10
An amount of 10 mMoles of sulfonamides 4a,b as hydrochloride was dissolved in a solution
obtained from 20 mMoles of NaOH and 15 mL water. The sulfonamide sodium salt obtained in this way
was treated with a solution of metal salt (MC12 .xH20, where M Co(II); Zn(II); and Cu(II) ), at molar
ratio sulfonamide M(II) of 2:1. The complexes 5-10 precipitated immediately, were filtered and air dried.
Yields were very good (85-95%). Presumably, in these conditions the chirality of centers present in the
thiopyran moiety of ligands 4 is not affected, as suggested by experimental data of ref.
7b
Results and Discussion
The new derivatives prepared in this study, containing sezolamide 4a and dorzolamide 4b as
ligands and the following metal ions, Co01); Zn(II) and Cu(II), of type 5-10, are shown in Table I, together
with their elemental analysis data (within + 0.4% of the theoretical values).
The prepared derivatives were further characterized by spectroscopic, magnetic and
conductimetric measurements. In Table II some of these data are shown, more specifically the sulfonamido
vibrations in the IR spectra of the ligands 4 and complexes 5-10, the electronic transitions in the diffuse
reflectance spectra of the complexes as well as magnetic and conductimetric data of these compounds.
The IR spectra of complexes 5-10 differ little from those of the original legends, except for the
two intense sulfonamide bands, which were shifted for the complexes with about 20 cm
-1 towards lower
wavenumbers as compared to the corresponding bands of the ligands. This behavior is well documented for
other complexes of heterocyclic sulfonamides, such as 1-3, previously reported, ,2,4,11,12 and clearly
indicates that the deprotonated sulfonamido moiety interacts with the metal ions, a fact confirmed by X-ray
crystallographic studies of several complexes containing acetazolamide 1, methazolamide 2 or other
sulfonamides of this type.
2,4c,11
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Table I: Complexes 5-10 prepared and their elemental analysis data.
No. Compound Color Analysis (calc./found.)
%M
a %C
b %H’ %N
b
5 [Co(SZA)2] violet 8.0/7.9 35.9/36.1 4.6/4.7 7.6/7.5
6 [Zn(SZA)2] white 8.8/8.5 35.6/35.5 4.6/4.4 7.5/7.5
7 [Cu(SZA)2(OH2)2] emerald 8.2/8.0 34.1/34.1 4.9/4.7 7.2/6.9
8 [Co(DZA)2] violet 8.3/8.0 34.0/33.8 4.2/3.9 7.9/7.8
9 [Zn(DZA)2] white 9.1/9.2 33.7/33.5 4.2/4.0 7.8/7.5
10 [Cu(DZA)2(OH2)2] blue 8.5/8.2 32.1/32.2 4.5/4.1 7.5/7.2
aBy gravimetry; bBy combustion
In the diffltse reflectance spectra of the Co(II) complexes 5 and 8, an intense band with three
maxima, around 16,250; 18,300, and 19,870 cm"1, respectively was evidenced, which is characteristic for
this ion in (distorted) tetrahedral geometry.
11-1s On the other hand, the magnetic moment of the Co(II)
derivatives, around 4.3 BM, is characteristic for this geometry of Co(II). 12"16For the two Cu(II) complexes,
7 and 10, a structureless wide band centered at 16,200 cm- was observed, similar to that of the
acetazolamide complexes of Cu(II) previously reported by us
4a and by Borras’ group.
11 Correlated with a
magnetic moment of 2.2BM at room temperature, this is typical of Cu(II) in octahedral surrounding.
11
Table II: Spectroscopic, magnetic and conductimetric data for complexes 5-10 as compared to ligands 4.
Comp. IR Spectra
a ,cm’l
v(SO2)S v(SO2)as
Electronic Spectra b, tteffe
v (cm-1) (BM)
Conductimetry d,
AN (gy1 xcmxmol-)
4a 1162 1368 114
5 1141 1347 16,245; 18,300; 19,870 4.35 24
6 1139 1348 28
7 1138 1346 16,200 2.21 19
4b 1159 1345 109
$ 1140 1327 16,250; 18,300; 19,860 4.31 34
9 1139 1327 27
10 1139 1326 16,200 2.23 35
a FTIR spectra of thin films of pure compound; b Diffuse reflectance spectra in MgO as reference; c At
room temperature by Faraday’s method;
d Solution 10-3 M, in DMF, at 25C
From the conductimetric data of Table II one can see that the ligands are 1:1 electrolytes due to
the fact that they are hydrochlorides. The same behavior was also observed for the corresponding sodium
salts (data not shown), in contrast to complexes 5-10, which are non-electrolytes. An interesting observation
was that these complexes possess a larger water solubility as compared to similar compounds, containing
sulfonamides 1-3 as ligands, previously reported.
2,4,17
From the above data one can conclude that the new sulfonamides 4 used for the preparation of
complexes in this study behave as bidentate ligands, similarly with the "classical" ligands of this type,
acetazolamide 1, methazolamide 2 and ethoxzolamide 3. But in contrast to these sulfonamides, derivatives 4
do not possess endocyclic nitrogen atoms. Thus, their donor system is constituted by the sulfonamide
(negatively charged) nitrogen, and the endocyclic sulfur atom. In this way five-membered chelate rings are
formed with the complexed metal ions. Mention should be made that only in a unique other case such a
donor system was previously evidenced for complexes of heterocyclic sulfonamides, i.e., in the dinuclear
18 Pt(II) complex of ethoxzolamide 3. In all other case the endocyclic nitrogens were preferred as
compared to the sulfur atoms for formation of chelate rings.
The geometry of central ions in the prepared complexes is supposedly tetrahedral for the Zn(II)
derivatives, pseudotetrahedral for the Co(II), and octahedral (with two coordinated water molecules) for the
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Cu(II) derivatives (mention should be made that the two water molecules are lost at temperatures over
170C (data not shown), supporting this statement).
Complexes 5-10 prepared in this study were tested for their ability to inhibit carbonic anhydrase
(bovine isozyme II was used in these assays). In Table III IC5o values are presented for these compounds,
comparatively with the corresponding data of the free ligands 4a,b.
Table III: CA II inhibition data with compounds 4-10, determined by Maren’s method.
10
Inhibitor 4a 4b 5 6 7 8 9 10
IC50 (nM) 0.60 0.25 0.15 0.18 0.09 0.10 0.12 0.07
It can be seen that all these compounds act as very potent CA II inhibitors. The parent ligands are
active in nanomolar concentrations, but due to their dual mechanism of action, the complexes of sezolamide
and dorzolamide are among the most potent CA inhibitors ever reported. In the series of the prepared
derivatives, the Cu(II) complexes of both ligands are the most potent inhibitors, followed by the Co(II) and
Zn(II) derivatives. Probably this can be correlated with the affinity of the corresponding cation to the CA II
proton shuttle, which is the active site residue His-64. 4,5
In conclusion, this is the first report of coordination compounds of two new sulfonamide
antiglaucoma agents, recently introduced in clinical use. In addition to contributing to the study of
coordination chemistry of such derivatives, the present study also highlights the putative use of these
complexes for developing novel types of pharmacological agents containing biologically relevant metal ions.
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